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Abstract
RECQL1, a keymember of the RecQ family of DNAhelicases, is
required for DNA replication and DNA repair. Two recent studies
have shown that germline RECQL1mutations are associated with
increased breast cancer susceptibility. Whether altered RECQL1
expression has clinicopathologic signiﬁcance in sporadic breast
cancers is unknown. We evaluated RECQL1 at the transcriptomic
level (METABRIC cohort, n ¼ 1,977) and at the protein level
[cohort 1, n ¼ 897; cohort 2, n ¼ 252; cohort 3 (BRCA germline
deﬁcient), n ¼ 74]. In RECQL1-depleted breast cancer cells, we
investigated anthracycline sensitivity. High RECQL1mRNA was
associated with intClust.3 (P ¼ 0.026), which is characterized
by low genomic instability. On the other hand, low RECQL1
mRNA was linked to intClust.8 [luminal A estrogen receptor–
positive (ERþ) subgroup; P ¼ 0.0455] and intClust.9 (luminal
B ERþ subgroup; P ¼ 0.0346) molecular phenotypes. Low
RECQL1 expression was associated with shorter breast can-
cer–speciﬁc survival (P ¼ 0.001). At the protein level, low
nuclear RECQL1 level was associated with larger tumor size,
lymph node positivity, high tumor grade, high mitotic index,
pleomorphism, dedifferentiation, ER negativity, and HER-2
overexpression (P < 0.05). In ERþ tumors that received endo-
crine therapy, low RECQL1 was associated with poor survival
(P ¼ 0.008). However, in ER tumors that received anthracy-
cline-based chemotherapy, high RECQL1 was associated with
poor survival (P ¼ 0.048). In RECQL1-depleted breast cancer
cell lines, we conﬁrmed doxorubicin sensitivity, which was
associated with DNA double-strand breaks accumulation,
S-phase cell-cycle arrest, and apoptosis. We conclude that
RECQL1 has prognostic and predictive signiﬁcance in breast
cancers. Mol Cancer Ther; 16(1); 239–50. 2016 AACR.
Introduction
DNA helicases unwind DNA, a process essential during repli-
cation and DNA repair. Human RecQ family of DNA helicases
includes RECQL1, RECQL4, RECQL5, BLM, and WRN (1, 2).
RECQL1 (also known as RECQL or RECQ1) is localized to
chromosome 12p12 and encodes a 649 amino acid protein
(3–6). RECQL1 is the smallest and the most abundant of human
RecQ helicases. RECQL1 is an integral component of the repli-
cation complex and is required for themaintenance of replication
fork progression (7–9). RECQL1 is also essential for the mainte-
nance of genomic stability through roles in DNA repair. RECQL1,
besides a DNA 30-50 helicase activity, can promote branch migra-
tion of Holliday junctions and also has strand annealing activity
(10). Moreover, to accomplish its various biological functions,
RECQL1 is known to interact with various proteins involved in
DNA repair, including PARP1, RPA, RAD51, Top3a, EXO1,
MSH2/6, MLH1-PMS2, and Ku70/80 (3–6). The essential role
played by RECQL1 in DNA repair is underpinned by the fact that
RECQL1 depletion in cells results in increased frequency of
spontaneous sister chromatid exchanges, chromosomal instabil-
ity, DNA damage accumulation, and increased sensitivity to
cytotoxic chemotherapy (11).
Emerging data suggest a role for RECQL1 in breast cancer
pathogenesis. Importantly, two recent studies have shown that
germline RECQL1mutations are associated with increased breast
cancer susceptibility (12–14). Sun and colleagues have identiﬁed
pathogenic mutations in RECQL1 gene in 9 of 448 Chinese
patients with BRCA-negative familial breast cancers (12). Simi-
larly, Cybulski and colleagues identiﬁed deleterious mutations in
7 of 1,013 and 30 of 13,136 Polish breast cancer patients (13).
Although germline mutations in RECQL1 are rare, the data
provide evidence that RECQL1 is a tumor suppressor. However
whether RECQL1 also inﬂuences sporadic breast cancer patho-
genesis and prognosis is currently unknown.
In the current study, we have comprehensively investigated
RECQL1 in large cohorts of sporadic breast cancer and have
provided the ﬁrst clinical evidence that altered RECQL1 expres-
sion is associated with aggressive breast cancers and poor
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prognosis. Preclinically, RECQL1 depletion in breast cancer cells
increased anthracycline chemosensitivity. We conclude that
RECQL1 expression has prognostic and predictive signiﬁcance
in sporadic breast cancers.
Materials and Methods
RECQL1 mRNA expression in breast cancer. RECQL1 mRNA
expression was investigated in METABRIC (Molecular Taxonomy
of Breast Cancer International Consortium) cohort. The METAB-
RIC study protocol, detailing the molecular proﬁling methodol-
ogy in a cohort of 1,977 breast cancer samples, is described by
Curtis and colleagues (15). Patient demographics are summarized
in Supplementary Table S1. Estrogen receptor–positive (ERþ)
and/or lymph node–negative patients did not receive adjuvant
chemotherapy. ER and/or lymph node–positive patients
received adjuvant chemotherapy. For this cohort, the mRNA
expression was hybridized to Illumina HT-12 v3 platform (Bead
Arrays), and the data were preprocessed and normalized as
described previously. RECQL1 expression was evaluated in this
dataset (RECQL1 probe ID: ILMN_1692705). The probe was a
perfect match and quality for its target, having a GC content of
58%, 0 SNPs, and it does not possess a polyG tail at the end.
Samples were classiﬁed into the intrinsic subtypes based on the
PAM50 gene list. A description of the normalization, segmenta-
tion, and statistical analyses was described previously (15). Real-
time qRT-PCRwas performed on the ABI Prism 7900HT sequence
detection system (AppliedBiosystems) using SYBR1Green report-
er. All the samples were analyzed as triplicates. The c2 test was
used for testing association between categorical variables, and a
multivariate Cox model was ﬁtted to the data using as endpoint
breast cancer–speciﬁc death. Xtile (Version 3.6.1) was used to
identify a cutoff in gene expression values such that the resulting
subgroups had signiﬁcantly different survival courses (16).
RECQL1 protein expression in breast cancer. The study was per-
formed in a consecutive series of 1,650 patients with primary
invasive breast carcinomas who were diagnosed between 1986
and 1999 and entered into the Nottingham Tenovus Primary
Breast Carcinoma series. Patient demographics are summarized in
Supplementary Table S2. This is a well-characterized series of
patientswith long-term follow-up that have been investigated in a
wide range of biomarker studies (17–23). All patientswere treated
in a uniform way in a single institution with standard surgery
(mastectomy or wide local excision), followed by radiotherapy.
Prior to 1989, patients did not receive systemic adjuvant
treatment (AT). After 1989, AT was scheduled on the basis of
prognostic and predictive factor status, including Nottingham
Prognostic Index (NPI), ERa status, and menopausal status.
Patients with NPI scores of <3.4 (low risk) did not receive AT.
In premenopausal patients with NPI scores of 3.4 (high risk),
classical cyclophosphamide, methotrexate, and 5-ﬂurouracil
(CMF) chemotherapy was given; patients with ERaþ tumors were
also offered endocrine therapy. Postmenopausal patients with
NPI scores of 3.4 and ERa positivity were offered endocrine
therapy, whereas ERa patients received classical CMF chemo-
therapy. Median follow-up was 111 months (range, 1–233
months). Survival data, including breast cancer–speciﬁc survival
(BCSS), disease-free survival (DFS), and development of locor-
egional and distant metastases (DM), were maintained on a
prospective basis. DFS was deﬁned as the number of months
from diagnosis to the occurrence of local recurrence, local lymph
node relapse or DM relapse. BCSS was deﬁned as the number of
months from diagnosis to the occurrence of breast cancer–related
death. Local recurrence-free survival was deﬁned as the number of
months from diagnosis to the occurrence of local recurrence. DM-
free survival was deﬁned as the number ofmonths fromdiagnosis
to the occurrence of DM relapse. Survival was censored if the
patient was still alive at the time of analysis, lost to follow-up, or
died from other causes.
We also evaluated an independent series of 252 ERa invasive
breast cancers diagnosed and managed at the Nottingham Uni-
versity Hospitals (Nottingham, United Kingdom) between 1999
and 2007. All patients were primarily treated with surgery, fol-
lowed by radiotherapy and anthracycline chemotherapy. The
characteristics of this cohort are summarized in Supplementary
Table S3. In addition, we also explored RECQL1 expression in a
cohort of BRCA germline-deﬁcient tumors. Patient demographics
in this cohort are summarized in Supplementary Table S4.
Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK) criteria, recommended by McShane and col-
leagues (24), were followed throughout this study. Ethical
approval was obtained from the Nottingham Research Ethics
Committee (C202313).
Tissue microarrays and IHC. Tumors were arrayed in tissue micro-
arrays (TMA) constructed with 0.6-mm cores sampled from the
periphery of the tumors. The TMAs were immunohistochemically
proﬁled for RECQL1 and other biological antibodies (Supple-
mentary Table S5) as described previously (18, 19, 21, 23).
Immunohistochemical staining was performed using the Thermo
Scientiﬁc Shandon Sequenza chamber system (REF: 72110017),
in combination with the Novolink Max Polymer Detection
System (RE7280-K: 1,250 tests), and the Leica Bond Primary
Antibody Diluent (AR9352), each used according to the manu-
facturer's instructions (Leica Microsystems). Leica Autostainer XL
machinewas used to dewax and rehydrate the slides. Pretreatment
antigen retrieval was performed on the TMA sections using
sodium citrate buffer (pH 6.0) and heated for 20minutes at 95C
in amicrowave (Whirlpool JT359 Jet Chef 1000W). A set of slides
was incubated for 60 minutes with the primary anti-RECQL1
antibody (Bethyl Laboratories, catalog no. A300-450A) at a dilu-
tion of 1:1,000, respectively. Negative and positive (by omission
of the primary antibody and IgG-matched serum) controls were
included in each run. The negative control ensured that all the
staining was produced from the speciﬁc interaction between
antibody and antigen.
Evaluation of immune staining.Whole-ﬁeld inspection of the core
was scored, and intensities of nuclear staining were grouped as
follows: 0 ¼ no staining, 1 ¼ weak staining, 2 ¼ moderate
staining, and 3¼ strong staining. The percentage of each category
was estimated (0%–100%). H-score (range, 0–300) was calcu-
lated bymultiplying intensity of staining and percentage staining.
RECQL1 expression was categorized on the basis of the frequency
histogram distributions. The tumor cores were evaluated by two
scorers (A. Arora and M.A. Aleskandarany), and the concordance
between the two scorers was excellent (k ¼ 0.79). Xtile (Version
3.6.1) was used to identify a cutoff in protein expression values
such that the resulting subgroups had signiﬁcantly different
survival courses. An H-score of 215 was taken as the cutoff for
high RECQL1 level. Not all cores within the TMAwere suitable for
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IHC assessments, as some cores were missing or containing
inadequate invasive cancer (<15% tumor).
Statistical analysis.Data analysiswasperformedusing SPSS (SPSS,
version 17). Where appropriate, Pearson c2, Fisher exact, Student
t, and ANOVA one-way tests were used. Cumulative survival
probabilities were estimated using the Kaplan–Meier method,
and differences between survival rates were tested for signiﬁcance
using the log-rank test. Multivariate analysis for survival was
performed using the Cox proportional hazards model. The pro-
portional hazards assumption was tested using standard log–log
plots. HRs and 95% conﬁdence intervals (95%CI)were estimated
for each variable. All tests were two-sided with a 95% CI and a
P value <0.05 considered signiﬁcant. For multiple comparisons,
P values were adjusted according to Benjamini–Hochberg
method (25).
Breast cancer cell lines and culture. MCF-7 (ERþ/PRþ/HER2,
BRCA1proﬁcient),MDA-MB-231 (ER/PR/HER2, BRCA1 pro-
ﬁcient),MDA-MB-468 (ER/PR/HER2, BRCA1proﬁcient), and
MDA-MB-436 (ER/PR/HER2, BRCA1 deﬁcient) were pur-
chased from ATCC and were grown in RPMI (MCF-7) or DMEM
(MDA-MB-231,MDA-MB-468, andMDA-MB-436)mediumwith
the addition of 10% FBS and 1%penicillin/streptomycin. Cells in
culturewere routinely checked formycoplasma contamination by
PCR (Sigma, catalog no. MP0035).The characterization of the
cells was performed by ATCC and passaged in the laboratory for
fewer than 6 months.
RECQL1 depletion in breast cancer cells. On-Target plus SMART-
pool siRNAs against RECQL1 (NM_032941) and nontargeting
control (CTL) were purchased from Dharmacon (catalog nos.
L-013597-00-0005 and D-001810-10-05, respectively). We have
previously established the speciﬁcity of the siRNA pool (5). All
siRNA transfections (inMCF-7,MDA-MB-231, andMDA-MB-468
breast cancer cells) were performed by reverse transfection at a
ﬁnal concentration of 20 nmol/L using Lipofectamine RNAiMAX
(Invitrogen, catalog no. 13-778-075) as instructed by the manu-
facturer. Stable shRNA-mediated knockdown of RECQL1 in
MDA-MB-231 cells was achieved using a lentiviral system (26).
Brieﬂy, lentivirus particles were produced by cotransfecting 293T
cells with the pLKO.1 lentiviral shRNA expression vector con-
taining the RECQL1 targeting sequence (50-GAGCTTATGTTAC-
CAGTTA-30) or the gene encoding luciferase (50-ACGCTGAG-
TACTTCGAAATGT-30) with the packaging plasmids psPAX2 and
pM2D.G and used to transduce MDA-MB-231 cells, followed by
selection with puromycin (8 mg/mL). All cells were cultured in a
humidiﬁed atmosphere containing 5%CO2at 37Cand routinely
checked for mycoplasma contamination (Sigma, catalog no.
MP0035). The level of RECQL1 depletion was veriﬁed byWestern
blotting.
Western blot analysis. Whole-cell lysates were prepared in RIPA
buffer containing protease inhibitor cocktail (Sigma, catalog no.
11873580001), and protein was quantiﬁed using Bio-Rad DC
Protein Assay Kit (Bio-Rad, catalog no. 5000111). Fifty micro-
grams of total protein per lane was used for immunoblotting. The
following primary antibodies were used: RECQL1 (1:1,000;
Bethyl Laboratories, catalog no. A300-450A), gH2AX (1:1,000;
Cell Signaling Technology, catalog no. 2577), GAPDH (1:1,000;
Cell Signaling Technology, catalog no. 5174), ERa (1:100, EP1
clone, Dako, catalog no. IS08430-2.), and b-actin (1:10,000;
Abcam, catalog no. ab8226). Following incubation with infrared
dye-labeled (Li-Cor; IRDye 800CW mouse anti-rabbit IgG and
IRDye 680CW rabbit anti-mouse IgG; 1:10,000) or HRP-conju-
gated secondary antibodies (Vector Laboratories) for 1 hour,
membranes were scanned with a Li-Cor Odyssey machine (700
and 800 nm) or GeneGnome XRQ Chemidoc System (Syngene)
to determine protein expression, and signal intensities were
quantiﬁed using ImageJ.
qRT-PCR. Total RNA was extracted from MCF-7, MDA-MB-231,
MDA-MB-468, and MDA-MB-436 cells using RNeasy Mini Kit
(QIAGEN). The quantiﬁcation of the extracted RNA was done
using a NanoDrop 2000c Spectrophotometer (Thermo Fisher
Scientiﬁc). The cDNA was synthesized from 0.5 mg of total RNA
using RT2 First Strand Kit (QIAGEN). The real-time qPCR was
performed using SYBR Green PCR Master Mix (Applied Biosys-
tems) with primer set (RECQL1 QuantiTect Primer Assay, catalog
no.QT00034503,QIAGEN) targeting RECQL1 gene. TheGAPDH
housekeeper gene was used as an internal control (GAPDH
QuantiTect Prier Assay, catalog no. QT00079247, QIAGEN).
The real-time PCR for each RNA sample was performed in trip-
licate. NTC (no template control) was used to rule out cross-
contamination of reagents and surfaces. NTC included all the
RT-PCR reagents except the RNA template. Minus reverse-tran-
scriptase ( RT) control was used to rule out genomic DNA
contamination.
Cytotoxicity and cell-cycle analysis. Cells, stably transduced or 48
hours after siRNA transfection, plated in quadruplicates into a 96-
well plate (5  103 cells/well) were treated with increasing
concentrations of doxorubicin, and cell viability was measured
after 5 days by the WST-8–based colorimetric assay using Cell
Counting Kit-8 (Dojindo Laboratories) according to the manu-
facturer's instructions. For cell-cycle analysis, cells were ﬁxed
in cold ethanol before being stained with propidium iodide
(Sigma, 0.45 mg/mL). Resuspended cells were analyzed for DNA
content by ﬂow cytometry performed on a BD Accuri C6 ﬂow
cytometer equipped with BD Accuri C6 software (BD Bio-
sciences). Means from two independent experiments were plot-
ted with their respective SEMs. Statistically signiﬁcant differences
between cell populations was conﬁrmed using a two-tailed t test,
assuming equal variances, and are presented in the ﬁgures as
, P  0.05; , P  0.005.
Immunoﬂuorescence staining analysis. For gH2AX staining, control
and RECQL1 knockdown cells were grown on coverslips in the
medium containing 0.1 mmol/L doxorubicin for 4 hours and
allowed to recover in drug-free medium for indicated time per-
iods. Cells were ﬁxed in 3.75% paraformaldehyde for 10 minutes
at room temperature, permeabilized in 0.5% Triton X-100 in PBS
for 10 minutes, and blocked with 1% BSA in PBS for 1 hour at
room temperature, followed by incubation with mouse mono-
clonal anti-gH2AX (1:200; Upstate Biotechnology, JBW301) anti-
body for 1 hour at 37C. After three washes in PBS for 5 minutes
each, the cells were incubated with Alexa Fluor 488 goat anti-
mouse IgG (1:400; Invitrogen) secondary antibody for 1 hour at
37C, washed three times with PBS, and mounted in ProLong
Gold containing DAPI (Invitrogen). Immunostained cells were
imaged with a Nikon ﬂuorescence microscope (Eclipse Ti)
equipped with imaging capabilities and Elements imaging
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software. Scoring for each individual condition (siRNA or shRNA,
cell line, drug treatment, etc.) within an experiment was carried
out on at least 10 separate ﬁelds of view and about 50 to 100 cells
in total. Means from two independent experiments were plotted
with their respective SEMs. Statistically signiﬁcant differences
between cell populations were conﬁrmed using a two-tailed
t test, assuming equal variances, and are presented in the ﬁgures
as , P  0.05; , P  0.005.
Results
RECQL1 mRNA expression in human breast cancer
We then evaluated RECQL1mRNA expression in the METABRIC
cohort. A total of 31.7% (626/1,971) of breast tumors had low
RECQL1 mRNA expression and 68.3% (1,345/1,971) of breast
tumors had high RECQL1 mRNA expression. Clinicopathologic
associations are summarized in Supplementary Table S6. The
METABRIC study by joint clustering of copy number and gene
expression data identiﬁed 10 novel biological subgroups [labeled
integrative clusters (intClust) 1–10; ref. 15]. We investigated
whether RECQL1 mRNA expression would associate with these
distinct biological subgroups (Supplementary Table S7). High
RECQL1mRNAwas associatedwith intClust.3 (P¼ 0.026),which
is characterized by low genomic instability (15). On the other
hand, low RECQL1mRNA was linked to intClust.8 (P ¼ 0.0455)
and intClust.9 (P ¼ 0.0346) phenotypes. Of note, intClust.8
belongs to luminal A ERþ subgroup, whereas intClust.9 belongs
to luminal B ERþ subgroup (15).
We then proceeded to survival analysis in the METABRIC
cohort. Low RECQL1mRNA expression was associated with poor
BCSS (P ¼ 0.001) in the whole cohort (Fig. 1B). In ERþ tumors,
low RECQL1 mRNA expression remained associated with poor
BCSS (P ¼ 0.001; Fig. 1C), including in patients who received
adjuvant endocrine therapy (P¼ 0.003; Fig. 1D).However, in ER
tumors, RECQL1 mRNA expression, although borderline, did
not signiﬁcantly inﬂuence outcome in the ER cohort, including
in patients who received adjuvant chemotherapy (P ¼ 0.071 and
P ¼ 0.071, respectively; Fig. 2E and F).
Together, the data provide evidence that RECQL1 mRNA level
has clinicopathologic and prognostic signiﬁcance in various sub-
types of breast cancers. We then proceeded to evaluate RECQL1
protein level in breast cancers.
RECQL1 protein level in human breast cancer
A total of 897 early breast cancers were suitable for RECQL1
expression analysis. We observed only nuclear expression where
677of 897 (75.5%) tumors had lowRECQL1 level and220of 897
(25.5%) had high RECQL1 level (Fig. 2B). We also evaluated 15
normal breast tissues for RECQL1 expression where high nuclear
staining in the terminal duct lobular units in the sections was
observed (mean H-score ¼ 226), suggesting differential expres-
sion of RECQL1 in breast cancer tissues compared with normal
breast tissue.No cytoplasmic stainingwas observed in any normal
breast or tumor tissue.
As shown in Table 1, in the whole cohort, low nuclear RECQL1
levels were signiﬁcantly associated with larger tumor size, lymph
node positivity, higher tumor stage, high tumor grade, high
mitotic index, pleomorphism, dedifferentiation, and tumor type
(Ps < 0.05). ER, progesterone-negative (PR), and HER-2 over-
expression was more common in tumors with low nuclear
RECQL1 protein level (P < 0.05). High-risk NPI >3.4 was also
more common in tumors with low RECQL1 level (P ¼ 0.0006).
Low PARP1, BRCA1 negative, low RAD51, low ATM, low nuclear
pChk1, low nuclear Chk2, low XRCC1, low FEN1, low SMUG1,
and low DNA-PKcs were signiﬁcantly more likely in tumors with
low nuclear RECQL1 protein level (P < 0.05). Moreover, low
RECQL1 tumors were also signiﬁcantly associated with low
levels of other RecQhelicases, including RECQL4, BLM, andWRN
(Ps < 0.05). We then proceeded to analysis separately in ERþ and
ER cohort.
In ERþ tumor (Supplementary Table S7), low nuclear RECQL1
level was signiﬁcantly associated with higher mitotic index (P ¼
0.033). PR and high-risk NPI >3.4 was also more common in
tumors with low RECQL1 level (P < 0.05). Low XRCC1 and low
TOPO2A were also more likely in tumors with low nuclear
RECQL1 protein level (P < 0.05). However, in ER tumors
(Supplementary Table S8), no signiﬁcant clinicopathologic asso-
ciations were observed.
We then proceeded to survival analyses. In the whole cohort,
patients whose tumors had low RECQL1 level were signiﬁcantly
more likely to have shorter BCSS compared with those with high
RECQL1 level (P¼ 0.001) (Fig. 2C). In ERþ tumors, similarly, low
RECQL1 was associated with poor BCSS (P ¼ 0.008; Fig. 2D),
including in patients who received adjuvant endocrine therapy
(P ¼ 0.021; Fig. 2E). However, in patients who received no
endocrine therapy, RECQL1 level did not inﬂuence survival
(P ¼ 0.485; Supplementary Fig. S1A). In ER tumors, RECQL1
did not inﬂuence survival, including in patients who received
CMF chemotherapy (Supplementary Fig. S1B–S1D). However, in
this historical cohort, patients received CMF chemotherapy,
which is currently not the standard adjuvant treatment in breast
cancer. We therefore investigated RECQL1 level and survival in a
further cohort of 252 ER tumors that received more modern
anthracycline-based adjuvant chemotherapies. The characteristics
of this cohort are summarized in Supplementary Table S3. As the
long-term follow-up data have not yet matured, we investigated
the impact of RECQL1 expression on DFS at 5 years in patients
who received adjuvant doxorubicin chemotherapy. At 5 years, 176
of 252 were alive, 73 of 252 were dead from breast cancer
recurrence, and 3 of 252 died from other causes. Patients with
high RECQL1 expression were more likely to suffer disease
recurrence compared with patients with low RECQL1 expression
(P ¼ 0.048; Fig. 2F).
We also investigated RECQL1 expression in 49 BRCA1 germ-
line-deﬁcient and 25 BRCA2 germline-deﬁcient breast tumors.
No signiﬁcant clinicopathologic associations were observed
(data not shown). RECQL1 expression also did not inﬂuence
survival outcomes of BRCA1/2 germline-deﬁcient tumors (data
not shown).
Taken together, the data suggest that RECQL1 overexpression
may predict resistance to doxorubicin chemotherapy in sporadic
ER breast cancers. To investigate this possibility further, we
proceeded to preclinical studies in breast cancer cell lines.
RECQL1 depletion and doxorubicin chemosensitivity in breast
cancer cell lines
RECQL1 deﬁciency leads to genomic instability and sensitivity
to a range of genotoxins (3–6). However, the impact of RECQL1
depletion in breast cancer cells and anthracycline sensitivity has
not been investigated.
We initially proﬁled MCF-7, MDA-MB-468, and MDA-MB
231 breast cancer cell lines. At the mRNA level, MCF-7 and
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MDA-MB-231 cells have high RECQL1 mRNA expression com-
pared with MDA-MB-468 cells (Fig. 3A). At the protein level, all
three cell lines have robust RECQL1 protein expression (Fig. 3B).
We then utilized siRNA to transiently deplete RECQL1 in MDA-
MB-468, MDA-MB-231, and MCF-7 cells. We transfected cells
with a control siRNA (siControl) or a pool of 4 siRNAs (SMART-
pool, 20 nmol/L) targeting RECQL1 (siRECQL1; Fig. 3C1 and
3D1 and Supplementary Fig. S2A1). As compared with control
cells, RECQL1-depleted cells displayed signiﬁcantly reduced sur-
vival to doxorubicin treatment in MDA-MB-468, MDA-MB 231
(Fig. 3C2 and 3D2), and MCF-7 cells (Supplementary Fig. S2A2;
P < 0.05 at all drug concentrations tested). To determine whether
increased sensitivity to doxorubicin was also sustained in cells
depleted of RECQL1 over a longer period of time, we transduced
MDA-MB-231 cells with a RECQL1-speciﬁc shRNA (Fig. 3E1).
As compared with control shRNA (shCTL)–transduced MDA-
MB-231 cells, the RECQL1 shRNA (shRECQL1)–transduced cells
displayed signiﬁcantly reduced survival to doxorubicin treatment
(Fig. 3E2).
To determine whether the cellular level of RECQL1 protein
modulates overall DNA damage in breast cancer cell lines, we
examined gH2AX as a surrogate of DNA double-strand breaks in
control and RECQL1 knockdown cells exposed to doxorubicin.
MDA-MB-231 cells stably transduced with control or RECQL1
shRNAwere treatedwith 0.1 mmol/L doxorubicin for 4 hours, and
the percentage of cells exhibiting 5 gH2AX foci at various time
points following recovery fromdrug treatmentwas determined by
immunoﬂuorescence (Fig. 3F). Consistent with constitutively
elevated DNA damage upon RECQL1 knockdown reported in
other cell types (8, 27), RECQL1-depleted MDA-MB-231 cells
displayed spontaneous gH2AX foci under untreated condition.
Doxorubicin treatment induced comparable level of DNA dou-
ble-strand breaks in both control and RECQL1 knockdown
MDA-MB-231 cells. However, following 8-hour recovery from
the doxorubicin treatment, signiﬁcantly greater fraction of
RECQL1-depleted cells was scored positive for gH2AX foci. After
24 hours in drug-free medium, gH2AX foci were persistent in
about 25% RECQL1-depleted cells as compared with 5% control
Figure 1.
RECQL1 mRNA expression and breast cancer survival. A, RECQL1 mRNA expression and survival in the whole cohort. B, RECQL1 mRNA expression and survival
in ERþ tumors. C, RECQL1 mRNA expression and survival in patients with ERþ tumors who received endocrine therapy. D, RECQL1 mRNA expression and
survival in ER tumors. E, RECQL1 mRNA expression and survival in patients with ER tumors who received chemotherapy. Cum, cumulative.
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MDA-MB-231 cells (Fig. 3G). We note that the initial numbers of
gH2AX-positive cells induced spontaneously in control versus
RECQL1-depleted cells are different; however, the difference
between control and RECQL1 knockdown cells for the percentage
of gH2AX-positive cells during recovery (8 and 24 hours) from
doxorubicin treatment is statistically signiﬁcant (P  0.05).
These results suggest that RECQL1 promotes repair of doxorubi-
cin-induced DNA damage. In MCF-7 cells, similarly, RECQL1-
depleted cells retain statistically signiﬁcant proportion of gH2AX-
positive cells at 8 and 24 hours following recovery in drug-free
medium (Supplementary Fig. S2B).
We next analyzed cell-cycle progression in these cells using
FACS analysis (Fig. 4). Stable knockdown of RECQL1 in MDA-
MB-231 cells resulted in predominant accumulation in G0–G1
phase of the cell cycle. Cell-cycle distribution of control and
RECQL1 knockdown MDA-MB-231 cells was largely unaltered
after doxorubicin treatment (0.1 mmol/L, 4 hours). MDA-MB-231
cells, with or without knockdown of RECQL1 expression, accu-
mulated in the S-phase following 8 hours after recovery from
treatment, and in G2–M following 24-hour recovery in drug-free
medium; however, a signiﬁcantly greater proportion of RECQL1-
depleted cells remained in the S-phase at 8 (P  0.05) and 24
hours (P  0.05) of recovery (Fig. 4A and B). Doxorubicin-
induced S-phase arrest is consistent with the formation of DNA
adducts that prevent replication fork progression and forma-
tion of double-strand breaks downstream of topoisomerase II
inhibition. Relative accumulation in the S-phase, together with
the increased double-strand breaks and sensitivity to doxoru-
bicin observed in RECQL1 knockdown MDA-MB-231 cells, is
consistent with a role of RECQL1 in resolving stalled or broken
replication forks and DNA repair. Doxorubicin-induced DNA
strand breaks can ultimately result in apoptosis. To determine
the extent of doxorubicin-induced cell death in RECQL1 knock-
down cells, we analyzed the percentage of MDA-MB-231 cells
stably transduced with control or RECQL1 shRNA having
sub-G1 DNA content (Fig. 4C and D). Following treatment
with doxorubicin (0.1 mmol/L) for 24 hours, 9  1.73% control
and 15  2.61% RECQL1 knockdown cells were in the sub-G1
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Figure 2.
RECQL1 protein level and breast cancer survival. A, Photomicrographs of RECQL1 protein expression in breast cancers. B, RECQL1 protein level and survival in the
whole cohort. C, RECQL1 protein level and survival in ERþ tumors. D, RECQL1 protein level and survival in patients with ERþ tumors who received endocrine
therapy. E, RECQL1 protein level and survival in patients with ER tumors who received anthracycline chemotherapy. Cum, cumulative.
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Table 1. RECQL1 protein levels and breast cancer
RECQL1 protein level P
Low High
Variable n (%) n (%) Unadjusted Adjusted
(A) Pathological parameters
Tumor size
<1 cm 53 (7.8) 31 (14.1) 0.031 0.0472
>1–2 cm 338 (49.9) 108 (49.1)
>2–5 cm 268 (39.6) 78 (35.5)
>5 cm 18 (2.7) 3 (1.4)
Lymph node status
Negative 351 (58.5) 143 (68.8) 0.029 0.0483
Positive (1–3) 199 (33.2) 54 (26.0)
Positive (>3) 50 (8.3) 11 (5.3)
Tumor stage
1 410 (60.5) 157 (70.7) 0.017 0.0313
2 210 (29.6) 52 (23.4)
3 67 (9.9) 13 (5.9)
Tumor grade
G1 88 (13.0) 46 (20.9) 0.0001 0.0018
G2 230 (33.9) 89 (40.5)
G3 360 (53.1) 85 (38.6)
Mitotic index
M1 (low; mitoses <10) 212 (32.2) 105 (48.2) 0.0001 0.0012
M2 (medium; mitoses 10–18) 131 (19.9) 34 (15.6)
M3 (high; mitoses >18) 315 (47.9) 79 (36.2)
Tubule formation
1 (>75% of deﬁnite tubule) 25 (3.8) 19 (8.7) 0.006 0.0162
2 (10%–75% deﬁnite tubule) 213 (32.4) 78 (35.8)
3 (<10% deﬁnite tubule) 420 (63.8) 121 (55.5)
Pleomorphism
1 (small-regular uniform) 13 (2.0) 7 (3.2) 0.001 0.0044
2 (moderate variation) 218 (33.2) 101 (46.5)
3 (marked variation) 425 (64.8) 109 (50.2)
Tumor type
IDC-NST 421 (63.3) 107 (49.5) 0.017 0.0298
Tubular carcinoma 122 (18.3) 59 (27.3)
Medullary carcinoma 17 (2.6) 6 (2.8)
ILC 63 (9.5) 27 (12.5)
Others 8 (1.2) 4 (1.9)
Mixed NST/lobular/special type 34 (5.1) 13 (6.0)
ER
Negative 187 (28.1) 42 (19.7) 0.015 0.0309
Positive 478 (71.9) 171 (80.3)
PR
Negative 310 (48.0) 67 (31.5) 0.0001 0.0007
Positive 336 (52.0) 146 (68.5)
Her2 overexpression
No 559 (84.1) 197 (90.0) 0.032 0.0431
Yes 106 (15.9) 22 (10.0)
Triple-negative phenotype
No 570 (83.8) 183 (81.7) 0.459 0.4725
Yes 110 (16.2) 41 (18.3)
NPI
3.4 117 (27.7) 88 (41.5) 0.0001 0.0006
>3.4 462 (72.3) 124 (58.5)
(B) DNA repair
XRCC1 (nuclear)
Low 98 (18.6) 9 (5.6) 0.0001 0.0005
High 430 (81.4) 151 (94.4)
BRCA1 (nuclear)
Low 104 (18.9) 18 (10.7) 0.014 0.0306
High 447 (81.1) 150 (89.3)
SMUG1 (nuclear)
Low 288 (58.2) 64 (45.1) 0.002 0.007
High 207 (41.8) 78 (54.9)
FEN1 (nuclear)
Low 389 (75.4) 103 (65.2) 0.012 0.0280
High 127 (24.6) 55 (34.8)
(Continued on the following page)
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population; treatment for 48 hours resulted in 13  2.04%
control and 19.2 2.01% RECQL1 knockdown cells in the sub-
G1 population (Fig. 4C and D). In RECQL1-depleted MCF-7
cells, although S-phase accumulation was not evident (Supple-
mentary Fig. S2C), there was a signiﬁcant accumulation of
sub-G1 cells upon 24 and 48 hours of doxorubicin treatment
(Supplementary Fig. S2D).
RECQL1 depletion and ERa levels
Given the recent evidence that RECQL1 may modulate gene
expression (26, 28), we conducted preliminary studies to explore
whetherRECQL1may impactuponERa expression inbreast cancer
cell lines. In control cells, as expected, ERa expression was not
detectable in MDA-MB-468 cells and MCF-7 cells had proﬁcient
ERa expression. We detected ERa expression in MDA-MB-231.
Table 1. RECQL1 protein levels and breast cancer (Cont'd )
RECQL1 protein level P
Low High
Variable n (%) n (%) Unadjusted Adjusted
FEN1 (cytoplasmic)
Low 285 (55.2) 70 (44.3) 0.016 0.0311
High 231 (44.8) 88 (55.7)
PARP1
Low 270 (49.0) 67 (39.6) 0.033 0.0481
High 281 (51.0) 102 (60.4)
TOPO2
Low 237 (47.0) 64 (38.6) 0.057 0.0739
High 267 (53.0) 102 (61.4)
KU 70/80
Low 60 (13.0) 22 (17.7) 0.181 0.2112
High 400 (87.0) 102 (82.3)
DNA-PKcs
Low 87 (18.0) 7 (5.6) 0.001 0.0044
High 397 (82.0) 117 (94.4)
ATR
Low 110 (35.4) 38 (37.6) 0.682 23.87
High 201 (64.6) 63 (62.4)
Chk1 (nuclear)
Low 605 (89.1) 164 (73.2) 0.0001 0.0005
High 74 (10.9) 60 (26.8)
Chk1 (cytoplasmic)
Low 211 (31.1) 75 (33.5) 0.451 0.478
High 468 (68.9) 149 (66.5)
ATM
Low 238 (56.9) 54 (41.5) 0.002 0.007
High 180 (43.1) 76 (58.5)
CHK2
Low 112 (25.2) 19 (15.7) 0.029 0.327
High 333 (74.8) 102 (84.3)
RAD51 (nuclear)
Low 234 (55.1) 43 (39.1) 0.003 0.0095
High 191 (44.9) 67 (60.9)
(C) Other RecQ helicases
RECQL5 (nuclear)
Low 273 (46.5) 68 (40.0) 0.133 0.1605
High 314 (53.5) 102 (60.0)
RECQL4 (nuclear)
Low 245 (65.9) 173 (50.6) 0.00004 0.0014
High 127 (34.1) 169 (49.4)
RECQL4 (cytoplasmic)
Low 297 (53.6) 73 (46.2) 0.100 0.125
High 257 (46.4) 85 (53.8)
BLM (nuclear)
Low 163 (27.7) 28 (16.9) 0.005 0.0146
High 426 (72.3) 138 (83.1)
BLM (cytoplasmic)
Low 438 (74.5) 114 (70.3) 0.292 0.3194
High 150 (25.5) 48 (29.6)
WRN (nuclear)
Low 197 (48.8) 53 (42.1) 0.188 0.214
High 207 (51.2) 73 (57.9)
WRN (cytoplasmic)
Low 221 (54.7) 52 (41.3) 0.008 0.02
High 183 (45.3) 74 (58.7)
NOTE: Bold ¼ statistically signiﬁcant; triple negative: ER/PR/HER2.
Abbreviations: IDC-NST, invasive ductal carcinoma-non-speciﬁc type; ILC, invasive lobular carcinoma.
Arora et al.
Mol Cancer Ther; 16(1) January 2017 Molecular Cancer Therapeutics246
on May 15, 2018. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Published OnlineFirst November 11, 2016; DOI: 10.1158/1535-7163.MCT-16-0290 
Although unexpected, previous studies have reported ERa expres-
sion in MDA-MB-231 cells (29, 30). As shown in Supplementary
Fig. S3, 48 hours after RECQL1 siRNA transfection, we observed
signiﬁcant depletion of ERa levels in MCF-7 and MDA-MB-231
cells. The data suggest that either RECQL1 depletion impairs ERa
expression or promotes ERa degradation. Detailed mechanistic
studies are currently under way to explore these possibilities.
Taken together, preclinical and clinical data provide evidence
that RECQL1 has prognostic and predictive signiﬁcance in breast
cancers.
Figure 3.
RECQL1 depletion and doxorubicin sensitivity in breast cancer cell lines. A, RECQL1mRNA expression in MCF-7, MDA-MB-231, and MDA-MB-468 breast cancer cell
lines. B, RECQL1 protein level in MCF-7, MDA-MB-231, and MDA-MB-468 breast cancer cell lines. C, Transient RECQL1 depletion by siRNA (C1) and doxorubicin
sensitivity in MDA-MB-468 (C2; the graph shows the cellular surviving fractions measured at different doses of doxorubicin treatment in control and
RECQL1-depleted cells. Surviving fraction values are the mean  SEM from three independent experiments). D, Transient RECQL1 depletion by siRNA
(D1) and doxorubicin sensitivity in MDA-MB-231 (D2; the graph shows the cellular surviving fractions measured at different doses of doxorubicin treatment
in control and RECQL1-depleted cells. Surviving fraction values are the mean  SEM from three independent experiments). E, Stable RECQL1 depletion by
shRNA (E1) and doxorubicin sensitivity in MDA-MB-231 (E2; the graph shows the cellular surviving fractions measured at different doses of doxorubicin
treatment in control and RECQL1-depleted cells. Surviving fraction values are the mean  SEM from three independent experiments). F, Representative
immunoﬂuorescence staining of gH2AX foci (green) and its "Merge" with nuclear DNA stain DAPI (blue) in control and RECQL1-depleted MDA-MB-231 cells is shown
here. G, Analysis of gH2AX foci in MDA-MB-231 cells stably transduced with control or RECQL1 shRNA. The percentage of cells exhibiting 5 gH2AX foci
at indicated time points following recovery from doxorubicin treatment (0.1 mmol/L for 4 hours) was determined by immunoﬂuorescence. Quantitative data shown
represent the average from two independent experiments with associated SEMs.
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Discussion
RECQL1 is a keymember of the RecQ family of DNA helicases.
RECQL1 has important roles in the maintenance of replication
fork progression, DNA repair, and gene expression mechanisms
(3–6). Recently, RECQL1 germline mutations were discovered in
non-BRCA hereditary breast cancer patients (12, 13), implying a
critical tumor-suppressive function for RECQL1. However, the
role of RECQL1 in cancer pathogenesis appears to be complex. In
normal cells, RECQL1 may function as a "caretaker of the
genome" (3–6). On the other hand, established tumors may be
dependent on RECQL1 to tolerate replication-induced DNA
damage, a feature seen in proliferating cancer cells. In fact,
RECQL1 has been shown to be overexpressed in glioblastoma
(31), hepatocellular carcinoma (32), ovarian cancers (33), mel-
anoma (34), and head and neck cancer models (35). Whether
RECQL1 also impacts sporadic breast cancer pathogenesis is
currently unknown. We have conducted comprehensive analysis
and demonstrated prognostic and predictive signiﬁcance of
RECQL1 in sporadic breast cancers.
Genomic analyses have revealed that breast cancer represents a
heterogeneous group of diseases with distinct prognostic out-
comes (15). In addition to ER, PR, and HER-2 expression status,
markers of proliferation and genomic stability appear to inﬂuence
biological and clinical behavior of breast cancers (15, 36, 37).
Given the role of RECQL1 in DNA replication and repair, we
anticipated differential roles of RECQL1 in various molecular
subtypes of breast cancers. As expected, high RECQL1mRNA was
associated with intClust.3, which is characterized by low genomic
instability (15). On the other hand, low RECQL1 mRNA was
linked to intClust.8 luminal A ERþ subgroup (low proliferating)
phenotype (15). Interestingly, low RECQL1 mRNA was also
observed in intClust.9 phenotype, which belongs to luminal B
subgroup, implying a more complex role for RECQL1 in this
subgroup. In the METABRIC cohort, low RECQL1 mRNA was
associated with poor survival. At the protein level, similarly, low
RECQL1 was associated with aggressive phenotypes and poor
survival, including in ERþ tumors. However, a limitation to the
current study is that mRNA expression and protein expression
studies were conducted in two independent cohorts. Although,
low levels of RECQL1 appear to be prevalent in the breast cancers,
themechanism for suchdownregulation is currently unknown. As
epigenetic silencing of the BRCA1 promoter has been reported in
up to 11% to 14% of breast tumors (37), it is likely that similar
mechanisms may be operating for RECQL1 in sporadic breast
cancers. An interesting observation was that we did not observe
any cytoplasmic staining for RECQL1. This is in contrast to the
cytoplasmic staining observed for BLM, RECQL4, and WRN in
breast cancers (16, 38, 39). The data suggest differential regulation
of localization for different RecQ helicases. In preclinical studies,
RECQL1 deﬁciency has been shown to promote genomic insta-
bility resulting in increased frequency of spontaneous sister
chromatid exchanges, chromosomal instability, DNA damage
accumulation, and mutagenesis (3–6). A "mutator phenotype"
(38) due to RECQL1 deﬁciencymay therefore promote aggressive
phenotypes in ERþ breast cancers. In the current study, we
observed that lowPARP1, BRCA1negative, lowRAD51, lowATM,
lownuclear pChk1, lownuclearChk2, lowXRCC1, lowFEN1, low
SMUG1, and low DNA-PKcs were signiﬁcantly more likely in
tumors with low nuclear RECQL1 protein level. The data suggest
that RECQL1 lossmay increase genomic instability, whichmay in
turn lead to dysregulation of other DNA repair factors, thereby
promoting a "mutator phenotype." A novel observation in the
Figure 4.
RECQL1 depletion and cell-cycle
progression. A, Cell-cycle
distributions of MDA-MB-231 cells
stably transduced with either control
or RECQL1 shRNA at the indicated
times following recovery from
doxorubicin (Dox) treatment
(0.1 mmol/L for 4 hours). B, Data
shown represent the average from
two independent experiments with
associated SEMs. Individual P values
are summarized as a table here.
C, Sub-G1 population in control and
RECQL1-depleted MDA-MB-231 cells
after doxorubicin treatment
(0.1 mmol/L) for indicated time.
D, Data shown represent the average
from two independent experiments
with associated SEMs. Individual P
values are summarized as a table here.
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current study is that low RECQL1 also inﬂuenced survival in ERþ
cohorts that received endocrine therapy, implying that RECQL1
could also have predictive signiﬁcance. Given the recent evidence
that RECQL1 may modulate gene expression (26, 28), we spec-
ulate that ER and/or ER-mediated gene expression could be
inﬂuenced by low RECQL1 in tumors. To explore this hypothesis,
we investigated ERa protein levels in control and RECQL1-
depleted breast cancer cells. We observed signiﬁcant depletion
of ERa levels inRECQL1-depletedMCF-7 andMDA-MB-231 cells.
The preliminary datawould suggest that either RECQL1depletion
impairs ERa expression or promotes ERa degradation. Therefore,
detailed mechanistic studies are required to explore these possi-
bilities in detail.
In ER subgroup, RECQL1 did not appear to inﬂuence survival
either in patient who received no chemotherapy or who received
historical CMF chemotherapy. Interestingly, in ER tumors that
received the more modern anthracycline chemotherapy, we
observed that overexpression of RECQL1 was associated with
poor DFS. The data suggest that ER tumors may be dependent
on RECQL1 to tolerate replication-induced DNA damage, such as
those induced by doxorubicin chemotherapy. To support this
hypothesis, we depleted RECQL1 in breast cancer cells. We not
only demonstrated doxorubicin sensitivity in RECQL1-depleted
cells but also showed that the observed sensitivity was associated
with DNA double-strand breaks accumulation, S-phase cell-cycle
arrest, and apoptosis.
RecQ family of DNA helicases includes RECQL1, RECQL4,
RECQL5, BLM, andWRN (1, 2).We have recently investigated the
expression of RECQL4, RECQL5, BLM, andWRN in breast cancers
(17, 39–41).Whereas highRECQL4, highRECQL5, andhighBLM
expressionswere associatedwith aggressive breast cancers (17, 39,
40), low WRN expression was linked to poor outcomes (41).
Interestingly,RecQhelicasemRNA levels are linked to biologically
distinct integrative clusters reported in theMETABRIC study (15).
For example, intClust 3 subgroup that is characterized by low
genomic instability was consistently seen with tumors with low
BLM, low RECQL4, and low RECQL5mRNA levels. On the other
hand, high RECQL1 or high WRN mRNA levels correlated to
intClust 3 subgroup. Similarly, intClust 9 (8q cis-acting/20qam-
pliﬁed mixed subgroup with aggressive phenotype) was more
common in tumors with high BLM, high RECQL4, high RECQL5,
low RECQL1, or low WRN mRNA levels. Taken together, the
mRNAandprotein expression datawould suggest that differential
helicase expressions lead to distinct molecular phenotypes. We
speculate that proliferative functions (of BLM, RECQL4, and
RECQL5 helicases) and genomic stability functions (of RECQL1
and WRN) may inﬂuence breast cancer pathogenesis. Moreover,
the data presented here would also suggest that RecQ helicase–
deﬁcient sporadic tumors may be suitable for a synthetic lethality
approach, an exciting new personalized treatment strategy recent-
ly demonstrated for PARP inhibitors in BRCA-deﬁcient cancers
(42). Moreover, given the recent development of helicase inhi-
bitors (1), such as those targeting BLM (43, 44), our data would
indicate potential application for these newhelicase inhibitors for
personalization of breast cancer therapy.
In conclusion, we have shown that RECQL1 has prognostic and
predictive signiﬁcance in breast cancer.
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